Pancreatic Cancer Research

ResearcherUniversity of VeronaActive in the last 2 years

Francesco Giovinazzo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-3392-9292; OpenAlex author ID A5043104109. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
62
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 3 papers · 2025: none · 2026: 1 paper

Papers 10

  1. Upfront surgery vs. neoadjuvant therapy in pancreatic cancer with venous involvement: a multicenter retrospective analysis. Co-author DOI 10.1007/s00423-026-04291-0↗
  2. Effect of peri-adventitial superior mesenteric artery dissection on margin status during pancreaticoduodenectomy for resectable pancreatic cancer: the DISSECT … Co-author DOI 10.1093/bjsopen/zrae075↗
  3. Robotic Vascular Resection in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Last author DOI 10.3390/jcm13072000↗
  4. New Frontiers in Pancreatic Cancer Management: Current Treatment Options and the Emerging Role of Neoadjuvant Therapy. Last author DOI 10.3390/medicina60071070↗
  5. Neoadjuvant Treatments for Pancreatic Ductal Adenocarcinoma: Where We Are and Where We Are Going. Co-author DOI 10.3390/jcm12113677↗
  6. A review of lifestyle and environment risk factors for pancreatic cancer. Co-author DOI 10.1016/j.ejca.2020.11.040↗
  7. Surgical Management of Non-Metastatic Pancreatic Cancer in the United Kingdom: Results of a Nationwide Survey on Current Practice. Co-author DOI 10.3389/fonc.2021.791946↗
  8. Gemcitabine-Based Neoadjuvant Treatment in Borderline Resectable Pancreatic Ductal Adenocarcinoma: A Meta-Analysis of Individual Patient Data. Co-author DOI 10.3389/fonc.2020.01112↗
  9. International Validation of the Eighth Edition of the American Joint Committee on Cancer (AJCC) TNM Staging System in Patients With Resected Pancreatic Cancer. Co-author DOI 10.1001/jamasurg.2018.3617↗
  10. Clinical implications of biological markers in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.suronc.2012.07.004↗

Closest collaborators

The 25 strongest of 62 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Keith John Roberts · 3 shared papers, 2021–2026 · strength 0.57
  2. Nikolaos A. Chatzizacharias · 2 shared papers, 2021–2024 · strength 0.35
  3. Giuseppe Malleo · 2 shared papers, 2018–2026 · strength 0.28
  4. Laura Maggino · 2 shared papers, 2018–2026 · strength 0.28
  5. Roberto Salvia · 2 shared papers, 2018–2026 · strength 0.28
  6. Sofia Dallavalle · 1 shared paper, 2024 · strength 0.26
  7. Victoria Zecchin Ferrara · 1 shared paper, 2024 · strength 0.26
  8. Giulio Belfiori · 1 shared paper, 2026 · strength 0.22
  9. Marco Del Chiaro · 1 shared paper, 2026 · strength 0.22
  10. Benediktas Kurlinkus · 1 shared paper, 2026 · strength 0.22
  11. Asif Halimi · 1 shared paper, 2026 · strength 0.22
  12. Eline S. Zwart · 1 shared paper, 2026 · strength 0.22
  13. Patrick Maisonneuve · 1 shared paper, 2026 · strength 0.22
  14. Johanna Laukkarinen · 1 shared paper, 2026 · strength 0.22
  15. Reea Ahola · 1 shared paper, 2026 · strength 0.22
  16. Ernesto Sparrelid · 1 shared paper, 2026 · strength 0.22
  17. Elena B. Rangelova · 1 shared paper, 2026 · strength 0.22
  18. Gabriella Lionetto · 1 shared paper, 2026 · strength 0.22
  19. Massimo Falconi · 1 shared paper, 2026 · strength 0.22
  20. Geert Kazemier M · 1 shared paper, 2026 · strength 0.22
  21. Stefano Crippa · 1 shared paper, 2026 · strength 0.22
  22. Guralp Onur Ceyhan · 1 shared paper, 2026 · strength 0.22
  23. James Michael Halle-Smith · 1 shared paper, 2024 · strength 0.22
  24. Sarah F. Powell-Brett · 1 shared paper, 2024 · strength 0.22
  25. Sara Zanini · 2 shared papers, 2012–2021 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.